pd 153035 has been researched along with Cancer of Ovary in 5 studies
4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline: structure given in first source
PD-153035 : A member of the class of quinazolines carrying a 3-bromophenylamino substituent at position 4 and two methoxy substituents at positions 6 and 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "EGF plus EGFR inhibitor-primed ovarian cancer cells display increased sensitivity to taxol-induced cell death, resistant to EGF-induced cell migration and cell proliferation as well as ERK and PI3K/AKT activation." | 1.35 | Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs. ( Amaral, A; Cao, C; Chu, W; Di, W; Kivlin, R; Lu, S; Sowa, A; Wan, Y; Yang, H, 2008) |
| "Using human ovarian cancer cell line Caov3 cells, we observed that TSA induced cell death in a time- and dose-dependent manner and also inhibited cell migration." | 1.33 | Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells. ( Di, W; Healey, S; Kouttab, N; Qiu, L; Sun, Y; Wan, Y; Wanebo, H; Yan, B; Zhou, C, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grunt, TW | 2 |
| Puckmair, K | 2 |
| Tomek, K | 2 |
| Kainz, B | 2 |
| Gaiger, A | 2 |
| Zhou, C | 1 |
| Qiu, L | 1 |
| Sun, Y | 1 |
| Healey, S | 1 |
| Wanebo, H | 1 |
| Kouttab, N | 1 |
| Di, W | 2 |
| Yan, B | 1 |
| Wan, Y | 2 |
| Wagner, R | 1 |
| Rünzler, D | 1 |
| Köhler, G | 1 |
| Zielinski, CC | 1 |
| Cao, C | 1 |
| Lu, S | 1 |
| Sowa, A | 1 |
| Kivlin, R | 1 |
| Amaral, A | 1 |
| Chu, W | 1 |
| Yang, H | 1 |
| Bergmann-Leitner, ES | 1 |
| Bennett, TA | 1 |
| Hacker, NF | 1 |
| Stromberg, K | 1 |
| Stetler-Stevenson, WG | 1 |
5 other studies available for pd 153035 and Cancer of Ovary
| Article | Year |
|---|---|
An EGF receptor inhibitor induces RAR-beta expression in breast and ovarian cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; ErbB Receptors; Female; G | 2005 |
Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells.
Topics: Acetylation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Chromones; Dose-Res | 2006 |
Upregulation of retinoic acid receptor-beta by the epidermal growth factor-receptor inhibitor PD153035 is not mediated by blockade of ErbB pathways.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Line, Tumor; CpG Islands; DNA Methylati | 2007 |
Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation | 2008 |
Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells.
Topics: Antigens, CD; Autocrine Communication; Carcinoma; Cell Adhesion; Cell Movement; Cell Size; DNA, Anti | 2001 |